SenesTech stock (US8123281036): Q1 earnings miss with 11% surge

SenesTech reported Q1 2026 EPS of -$0.39, improving from -$1.28 year-ago but missing some estimates, as shares jumped 11% amid narrowing losses.

SenesTech, Inc. released its Q1 2026 earnings on May 13, 2026, posting an EPS of -$0.39, a 69.5% improvement from -$1.28 in Q1 2025, though some reports noted a beat against expectations of -$0.33 with reported -$0.31. Despite the per-share loss narrowing, the overall net loss widened. The stock surged 11% following the release, according to AInvest as of 05/13/2026 and Insider Monkey as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SenesTech, Inc.
• Sector/industry: Biotechnology / Pest Control
• Headquarters/country: United States
• Core markets: North America
• Key revenue drivers: ContraPest fertility control products
• Home exchange/listing venue: Nasdaq (SNES)
• Trading currency: USD

SenesTech: core business model

SenesTech develops and commercializes non-lethal rodent fertility control products, primarily ContraPest, a liquid bait that reduces rat populations by inducing temporary infertility in both sexes. The company targets commercial, governmental and residential pest management markets, offering an alternative to traditional rodenticides. Headquartered in Phoenix, Arizona, SenesTech focuses on sustainable pest control solutions amid growing demand for eco-friendly options, according to its investor relations site as of 05/14/2026.

Main revenue and product drivers for SenesTech

Revenue stems mainly from sales of ContraPest and related bait stations, with key drivers including partnerships with pest control operators and expansion into municipal contracts. In Q1 2026, the company continued efforts to scale commercialization, though specific revenue figures were not detailed in initial reports. Growth depends on regulatory approvals, field trial successes and adoption in high-rodent-density areas like urban centers.

Industry trends and competitive position

The global pest control market, valued at over $20 billion in 2025 per industry reports, sees rising demand for non-toxic solutions due to bans on certain rodenticides and ESG pressures. SenesTech positions itself against chemical giants like Rentokil Initial and Rollins, emphasizing biotech innovation. Its Nasdaq listing provides US investors exposure to this niche within biotechnology and sustainability sectors.

Why SenesTech matters for US investors

Listed on Nasdaq as SNES, SenesTech offers US retail investors a play on innovative pest management amid urbanization and regulatory shifts favoring green tech. Its focus on the US market, with potential in food safety and public health, ties into domestic trends like rodent control in cities.

Conclusion

SenesTech's Q1 2026 results showed progress in loss reduction despite a wider net loss, sparking an 11% stock rally. The company advances its biotech pest control mission, navigating commercialization challenges. Investors track upcoming quarters for revenue traction and market adoption.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.